Difference between revisions of "Fulvestrant (Faslodex)"
Jump to navigation
Jump to search
m (Text replace - "package insert<ref name="insert"></ref>." to "prescribing information.<ref name="insert"></ref>") |
m |
||
| Line 5: | Line 5: | ||
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | ||
| + | |||
| + | ==Diseases for which it is used== | ||
| + | *[[Breast cancer]] | ||
==Patient drug information== | ==Patient drug information== | ||
*[http://chemocare.com/bio/fulvestrant.asp Fulvestrant (Faslodex) patient drug information (Chemocare)]<ref>[http://chemocare.com/bio/fulvestrant.asp Fulvestrant (Faslodex) patient drug information (Chemocare)]</ref> | *[http://chemocare.com/bio/fulvestrant.asp Fulvestrant (Faslodex) patient drug information (Chemocare)]<ref>[http://chemocare.com/bio/fulvestrant.asp Fulvestrant (Faslodex) patient drug information (Chemocare)]</ref> | ||
*[http://www.uptodate.com/contents/fulvestrant-patient-drug-information Fulvestrant (Faslodex) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/fulvestrant-patient-drug-information Fulvestrant (Faslodex) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/fulvestrant-patient-drug-information Fulvestrant (Faslodex) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/fulvestrant-patient-drug-information Fulvestrant (Faslodex) patient drug information (UpToDate)]</ref> | ||
| + | |||
| + | ==History of changes in FDA indication== | ||
| + | * 4/25/2002: Initial FDA approval for "the treatment of [[Breast cancer | hormone receptor positive metastatic breast cancer]] in postmenopausal women with disease progression following antiestrogen therapy. | ||
==References== | ==References== | ||
<references/> | <references/> | ||
| + | |||
| + | [[Category:Drug index]] | ||
| + | [[Category:Endocrine therapy]] | ||
| + | [[Category:Estrogen receptor inhibitors]] | ||
| + | |||
| + | [[Category:Breast cancer medications]] | ||
| + | |||
| + | [[Category:Drugs FDA approved in 2002]] | ||
Revision as of 23:31, 29 October 2014
General information
Class/mechanism: Estrogen receptor antagonist; competitively binds to the estrogen receptor (ER) and downregulates estrogen receptor expression.[1][2]
Route: IM
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Fulvestrant (Faslodex) patient drug information (Chemocare)[3]
- Fulvestrant (Faslodex) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 4/25/2002: Initial FDA approval for "the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.